Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T17:03:50.477Z.
Calculation as of: 2026-10-06T17:03:50.477Z.
Quote observation: 2026-10-06T17:00:51.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 09a0ab09da9db255713b3d52bc1d4f6ff3c974c87d2899d50b33d975ee1631b8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Prelude Therapeutics Incorporated
Market Cap
$213.21M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$213.44M
Free Cash Flow Yield
2.66%
TTM Avg
2.46%
3Y Avg
2.61%
5Y Avg
2.53%
Market Cap
$211.48M
Free Cash Flow Yield
N/A
TTM Avg
41.32%
3Y Avg
41.21%
5Y Avg
35.11%
Market Cap
$216.34M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$209.05M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$207.98M
Free Cash Flow Yield
N/A
TTM Avg
10.09%
3Y Avg
10.09%
5Y Avg
10.09%
Market Cap
$206.61M
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$206.06M
Free Cash Flow Yield
3.34%
TTM Avg
3.60%
3Y Avg
5.22%
5Y Avg
5.17%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Prelude Therapeutics Incorporated (PRLD) | $213.21M | N/A | N/A | N/A | N/A |
| Niagen Bioscience Inc (NAGE)vs › | $213.44M | 2.66% | 2.46% | 2.61% | 2.53% |
| Alector, Inc. (ALEC)vs › | $211.48M | N/A | 41.32% | 41.21% | 35.11% |
| Compugen Ltd. (CGEN)vs › | $211.33M | N/A | N/A | N/A | N/A |
| Anbio Biotechnology Class A Ordinary Shares (NNNN)vs › | $216.34M | N/A | N/A | N/A | N/A |
| Sionna Therapeutics, Inc. (SION)vs › | $209.05M | N/A | N/A | N/A | N/A |
| Cartesian Therapeutics, Inc. (RNAC)vs › | $207.98M | N/A | 10.09% | 10.09% | 10.09% |
| Electra Therapeutics Inc. (ETRA)vs › | $206.61M | N/A | N/A | N/A | N/A |
| Pro-Dex, Inc. (PDEX)vs › | $206.06M | 3.34% | 3.60% | 5.22% | 5.17% |
| Lyell Immunopharma, Inc. (LYEL)vs › | $220.74M | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
